Diseases : DID38589 - Secondary Neoplasm

ZScoreRScoreEntity TypeIDNameSynonyms
2.4876119628 50 - [0, 0, 1, 5] Diseases DID38589 Secondary Neoplasm Secondary Neoplasm; METS; Secondary Cancer; metastatic disease; Metastatic Neoplasm; Metastasize; Secondary Tumor; Secondary malignant deposit; Metastatic malignant disease; Metastatic Tumor; Secondary tumour; Metastatic Malignant Neoplasm; Tumor, metastatic; Neoplasm Metastases; Tumour metastasis; Tumor metastasis; metastatic cancer; cancer, metastatic; METC; Secondaries; Secondary malignancies; Secondary neoplasm; Tumor Cell Migration
Back to View Results

RScore Document Snippets Details
50 - [0, 0, 1, 5] Association between Heavy Metals, Bisphenol A, Volatile Organic Compounds and Phthalates and Metabolic Syndrome.
[MEDLINE : 30823556]
(2019) Association between Heavy Metals, Bisphenol A, Volatile Organic Compounds and Phthalates and Metabolic Syndrome. International journal of environmental research and public health;Int J Environ Res Public Health;2019 02;16(4):

- Although many studies have revealed the relationship between heavy metals (cadmium, mercury, and lead), the sum of metabolites of di (2-ethylhexyl) phthalate (DEHP), and MetS, the results remain inconsistent.

- Multiple logistic regression analysis was performed for MetS with log-transformed hazardous material quartiles after covariate adjustment.

- Urine muconic acid (MuA) and mono- (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) levels were significantly associated with MetS after adjusting for confounders (odds ratio: 1.34 and 1.39, respectively).

- This cross-sectional study of a representative sample of adult South Koreans aimed to evaluate the relationship between heavy metals, VOC metabolites, phthalate metabolites, bisphenol A and MetS after adjusting for demographic variables.

- Urine MuA and MEHHP levels were significantly associated with MetS.

- The incidence of metabolic syndrome (MetS), which causes heart disease and stroke, has increased significantly worldwide.

Back to View Results

This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $900 million in funding from the federal government.